Abiopharma

🔍 Steffan Timothy (Executive)

Company: Comstock Holding Companies, Inc. (CHCI)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Acquired 5,774 shares of Class A Common Stock, $0.01 par value (Direct)
  Date: 2026-03-17 | Code: A | equity_swap_involved: false | shares_owned_after: 106,420.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,489 shares of Class A Common Stock, $0.01 par value at $14.31 per share (Direct)
  Date: 2026-03-17 | Code: F | equity_swap_involved: false | shares_owned_after: 103,931.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 15,000 shares of Class A Common Stock, $0.01 par value at $3.3 per share (Direct)
  Date: 2026-03-18 | Code: M | equity_swap_involved: false | shares_owned_after: 118,931.00 | transaction_form_type: 4
• Sold 8,424 shares of Class A Common Stock, $0.01 par value at $15.2 per share (Direct)
  Date: 2026-03-18 | Code: F | equity_swap_involved: false | shares_owned_after: 110,507.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 15,000 shares of Stock Options (Right to Buy) at $3.3 per share (Derivative)
  Date: 2026-03-18 | Code: M | Expires: 2028-06-27 | Exercise: 2022-06-27 | equity_swap_involved: false | shares_owned_after: 35,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Reflects vesting of performance-based restricted stock units
• F2: This transaction was executed in multiple trades at prices ranging from $15.06 to $15.34 USD; the price reported above reflects the weighted-average sale price. The reporting person hereby undertakes, upon request, to provide to Comstock Holding Companies, Inc. (the "Issuer"), any security holder ofthe Issuer, or the Securities and Exchange Commission, full information regarding the number of shares and prices at which the transaction was effected.
• F3: The stock options vested in four (4) equal annual installments, beginning on 6/27/2019 (the first anniversary of the grant date) and became fully vested and exercisable on this date